{"entity":{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","aka":[],"tldr":"Chinese ADC developer whose TROP2 ADC sac-TMT was licensed to Merck in one of the largest China-out deals.","summary":"Sichuan Kelun-Biotech, based in Chengdu and listed in Hong Kong as 6990.HK, is the Chinese antibody-drug conjugate developer whose TROP2 ADC sacituzumab tirumotecan, or sac-TMT, was licensed to Merck in one of the largest China-out deals, worth up to 9.3 billion dollars. Sac-TMT was the first TROP2 ADC approved in China, MK-3120 is its Nectin-4 ADC, and a broad ADC platform sits behind the Merck partnership, with Binghe Xu among the investigators linked. OnCo connects it to triple-negative breast cancer, to the TROP2 ADC roadmap that runs from sacituzumab govitecan through datopotamab deruxtecan to sac-TMT, to Sichuan Cancer Hospital and to the NMPA. Whether sac-TMT can repeat its Chinese results in Western trials is the open question. Sacituzumab tirumotecan has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.kelun-biotech.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":[],"drugs":["sacituzumab-tirumotecan","kl-a167","a166","skb105"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06670196","nct06448312","nct06711900","nct05870319","nct04152499","nct07296809","nct05351788","nct07622186","nct05816252","nct07329322","nct06081959","nct07459998","nct07700667","nct07341100","nct05347134","nct05642780","nct05265091","nct07230405","nct07697586","nct07448922","nct07299825","nct07586943","nct06279364","nct07308106","nct07324629","nct07545265","nct05631262","nct07019675","nct07071337"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Chengdu","country":"CN","companyType":"biotech","website":"https://www.kelun-biotech.com","ticker":"6990.HK","investors":[],"funding":[]},"route":"/companies/kelun-biotech/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"drug":[{"id":"a166","kind":"drug","name":"A166","route":"/drugs/a166/"},{"id":"kl-a167","kind":"drug","name":"KL-A167","route":"/drugs/kl-a167/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"},{"id":"skb105","kind":"drug","name":"SKB105","route":"/drugs/skb105/"}],"trial":[{"id":"nct07814066","kind":"trial","name":"A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastati","route":"/trials/nct07814066/"},{"id":"nct07308106","kind":"trial","name":"A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities","route":"/trials/nct07308106/"},{"id":"nct07230405","kind":"trial","name":"A Phase II Study of SKB571 in Patients With Lung Cancer","route":"/trials/nct07230405/"},{"id":"nct05870319","kind":"trial","name":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","route":"/trials/nct05870319/"},{"id":"nct07299825","kind":"trial","name":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07299825/"},{"id":"nct06968585","kind":"trial","name":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","route":"/trials/nct06968585/"},{"id":"nct05265091","kind":"trial","name":"A Study of KL590586 in Patients With Advanced Solid Tumors","route":"/trials/nct05265091/"},{"id":"nct05816252","kind":"trial","name":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-","route":"/trials/nct05816252/"},{"id":"nct06670196","kind":"trial","name":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan","route":"/trials/nct06670196/"},{"id":"nct06711900","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P","route":"/trials/nct06711900/"},{"id":"nct06448312","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06448312/"},{"id":"nct06279364","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06279364/"},{"id":"nct07071337","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","route":"/trials/nct07071337/"},{"id":"nct07448922","kind":"trial","name":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct07448922/"},{"id":"nct07019675","kind":"trial","name":"A Study of SKB518 in Patients With Lung Cancer","route":"/trials/nct07019675/"},{"id":"nct07622186","kind":"trial","name":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07622186/"},{"id":"nct05294172","kind":"trial","name":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct05294172/"},{"id":"nct04152499","kind":"trial","name":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","route":"/trials/nct04152499/"},{"id":"nct07329322","kind":"trial","name":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto","route":"/trials/nct07329322/"},{"id":"nct07501169","kind":"trial","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct07501169/"},{"id":"nct07324629","kind":"trial","name":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","route":"/trials/nct07324629/"},{"id":"nct07343479","kind":"trial","name":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","route":"/trials/nct07343479/"},{"id":"nct07459998","kind":"trial","name":"SKB103 for Injection in Advanced Solid Tumors","route":"/trials/nct07459998/"},{"id":"nct07380386","kind":"trial","name":"SKB105 for Injection in Advanced Solid Tumors","route":"/trials/nct07380386/"},{"id":"nct07586943","kind":"trial","name":"SKB118 Injection in Advanced Solid Tumors","route":"/trials/nct07586943/"},{"id":"nct05351788","kind":"trial","name":"SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.","route":"/trials/nct05351788/"},{"id":"nct05642780","kind":"trial","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","route":"/trials/nct05642780/"},{"id":"nct07697586","kind":"trial","name":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","route":"/trials/nct07697586/"},{"id":"nct05347134","kind":"trial","name":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct05347134/"},{"id":"nct05631262","kind":"trial","name":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","route":"/trials/nct05631262/"},{"id":"nct07700667","kind":"trial","name":"SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma","route":"/trials/nct07700667/"},{"id":"nct07296809","kind":"trial","name":"SKB500 Combinations in Patients With Small Cell Lung Cancer","route":"/trials/nct07296809/"},{"id":"nct07545265","kind":"trial","name":"SKB565 for Injection in Advanced Solid Tumors","route":"/trials/nct07545265/"},{"id":"nct06081959","kind":"trial","name":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06081959/"},{"id":"nct07341100","kind":"trial","name":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","route":"/trials/nct07341100/"},{"id":"nct07819578","kind":"trial","name":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","route":"/trials/nct07819578/"}],"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"roadmap":[{"id":"trop2-adc-roadmap","kind":"roadmap","name":"TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET","route":"/roadmaps/trop2-adc-roadmap/"}],"person":[{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/"}],"institution":[{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/"},{"id":"sichuan-cancer-hospital","kind":"institution","name":"Sichuan Cancer Hospital","route":"/institutions/sichuan-cancer-hospital/"}]}}